FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

ペプチドライブラリー

CagriSema

Cagrilintide + Semaglutide

Weight Loss & Metabolic

CagriSema is a fixed-ratio combination of semaglutide (a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analog), both developed by Novo Nordisk. This dual-mechanism injectable targets two complementary appetite and metabolic pathways simultaneously. It is in Phase 3 clinical trials and represents Novo Nordisk's next-generation obesity treatment strategy following semaglutide monotherapy.

作用機序

Fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist). Targets three distinct appetite and metabolic pathways simultaneously.

研究プロトコル

研究目的のみで使用。医療アドバイスではありません。

Research protocols use the combination in a single weekly injection. Phase 3 doses range from cagrilintide 2.4mg + semaglutide 2.4mg weekly.

研究ノート

Clinical Research Status

CagriSema is in Phase 3 trials (REDEFINE program) for obesity and type 2 diabetes, with regulatory submissions anticipated based on trial readouts. Phase 2 data demonstrated approximately 15.6% body weight loss at 32 weeks, numerically superior to semaglutide 2.4mg alone. The REDEFINE 1 Phase 3 trial reported up to 22.7% weight loss at 68 weeks, positioning it competitively against tirzepatide.

Key Published Findings

The dual amylin/GLP-1 approach produces additive weight loss beyond either mechanism alone, supporting the hypothesis that multi-receptor targeting enhances metabolic outcomes. Glycemic improvements were also observed, with potential for combined diabetes and obesity indications. The mechanistic rationale rests on amylin's distinct CNS satiety signaling through the area postrema complementing GLP-1's hypothalamic and gut-mediated effects.

Safety Profile

The adverse event profile combines elements of both components, with gastrointestinal effects (nausea, vomiting, diarrhea) being most common during dose escalation. Tolerability appears manageable with appropriate titration schedules, though direct comparisons to monotherapy discontinuation rates are still being evaluated. Injection site reactions are consistent with other subcutaneous peptide therapies.

Comparison to Related Compounds

CagriSema competes directly with tirzepatide (Mounjaro/Zepbound), which uses a single molecule targeting GIP and GLP-1 receptors simultaneously. The two-molecule approach allows independent dose optimization of each component but requires a single co-formulated injection. Weight loss magnitude appears comparable to tirzepatide's 20-25% in similar trial durations, though head-to-head data is needed for definitive comparison.

Community Observations

The obesity research community views CagriSema as Novo Nordisk's answer to tirzepatide's superior weight loss over semaglutide monotherapy. Clinicians note that the combination format may offer flexibility for patients who plateau on GLP-1 monotherapy. The amylin component is reported to address residual hunger that some patients experience even at maximum GLP-1 doses.

半減期

~7 days (combination)

再構成

Pre-mixed formulation

保存

乾燥粉末

Refrigerate 2-8C.

再溶解

Refrigerate 2-8C. Use within 42 days.

米国法的状況

Research chemical (not FDA-approved)

また知られる名前

Cagrilintide + Semaglutide

よくある質問

CagriSemaとは何ですか?

CagriSema is a fixed-ratio combination of semaglutide (a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analog), both developed by Novo Nordisk. This dual-mechanism injectable targets two complementary appetite and metabolic pathways simultaneously. It is in Phase 3 clinical trials and represents Novo Nordisk's next-generation obesity treatment strategy following semaglutide monotherapy.

CagriSemaはどのように作用しますか?

Fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist). Targets three distinct appetite and metabolic pathways simultaneously.

CagriSemaの米国での規制状況は?

Research chemical (not FDA-approved)

CagriSemaの半減期は?

~7 days (combination)

CagriSemaの別名は?

Cagrilintide + Semaglutide

ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。

完全な免責事項を読む